Search
PI-103
go.drugbank.com/drugs/DB17046ExperimentalPI-103 is an inhibitor of p110α of class I PI3K.[A253092]
PF-04217903
go.drugbank.com/drugs/DB12848InvestigationalPF-04217903 has been used in trials studying the treatment of Neoplasms.
PF-477736
go.drugbank.com/drugs/DB12611InvestigationalPF-00477736 has been used in trials studying the treatment of Neoplasms.
Hypercholesterolemia, Autosomal Dominant
go.drugbank.com/conditions/DBCOND0037437Synonyms: LDL receptor disorder, LDL - Low density lipoprotein receptor disorderDienogest
go.drugbank.com/drugs/DB09123ApprovedInvestigationalDienogest is an orally-active semisynthetic progestogen which also possesses the properties of 17α-hydroxyprogesterone. It is a derivative of 19-nortestosterone and has antiandrogenic properties. It is primarily used as a contraceptive i...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesPF-03758309
go.drugbank.com/drugs/DB11775InvestigationalPF-03758309 has been used in trials studying the treatment of Advanced Solid Tumors.
Salts: Pf 03758309 HydrochlorideBurosumab
go.drugbank.com/drugs/DB14012ApprovedInvestigationalSome adults with this condition suffer from persistent, unrelenting discomfort and complications, such as joint pain, impaired mobility, tooth abscesses and hearing loss [L2346].
Salsalate
go.drugbank.com/drugs/DB01399ApprovedInvestigationalIn contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo.
Bezisterim
go.drugbank.com/drugs/DB05212InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesPF-06273340
go.drugbank.com/drugs/DB12269InvestigationalPf 06273340 is under investigation in clinical trial NCT01934738 (A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects